Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

Exclusion Criteria

• •Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the Investigator.
• •Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the Investigator.
• •Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the Investigator.
• •Is pregnant, nursing an infant, or planning a pregnancy during the study period.
• •Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives (whichever is longer) prior to the Baseline visit or is concurrently participating in another clinical study with an investigational drug or device.